Your session is about to expire
← Back to Search
Whole-Body Periodic Acceleration Therapy for Pain (Exer-Rest Trial)
Phase 3
Waitlist Available
Research Sponsored by Center for Translational Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Available for regular visits to the research site for the duration of the study
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights
Exer-Rest Trial Summary
This trial will test if a new treatment, whole body periodic acceleration, can help reduce aches and pains for patients.
Who is the study for?
This trial is for adults over 18 who have chronic pain, joint stiffness, or problems with walking and balance. They must be evaluated by a doctor for these issues, handle the motion of WBPA therapy, and commit to regular study visits. Pregnant individuals, those with unexplained leg pain, skin conditions, unstable spine injuries or intolerance to WBPA's motion are excluded.Check my eligibility
What is being tested?
The trial is testing Whole-Body Periodic Acceleration (WBPA) therapy to see if it can relieve symptoms like aches and pains. Participants will undergo this non-invasive treatment regularly while their symptoms are monitored through tests like qEEG and questionnaires.See study design
What are the potential side effects?
While specific side effects aren't listed for WBPA therapy in the provided information, common concerns may include discomfort from the motion or potential worsening of balance issues during treatment.
Exer-Rest Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can attend all required study visits.
Exer-Rest Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Self-report of pain
Secondary outcome measures
Quality of life
Find a Location
Who is running the clinical trial?
Center for Translational MedicineLead Sponsor
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I can complete special tests and questionnaires for the study.I experience chronic pain, stiff joints, and problems with walking or balance.I am not pregnant, don't have unexplained leg pain or skin issues, and my spine is stable.I can handle the movement and length of the whole-body treatment.I can attend all required study visits.I cannot stay still for long periods required by the treatment.I am over 18 years old.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are subjects in this research project restricted to a certain age demographic?
"The age range for participants in this study is from 18 to 65 years old."
Answered by AI
Are there any eligibility requirements to join this research project?
"Eligible individuals for this study must be aged 18-65 and have a diagnosed balance disorder. Currently, the research team is looking to recruit 30 patients."
Answered by AI
Does this medication have the FDA's blessing?
"This particular Phase 3 trial has garnered enough evidence of safety to be given a 3."
Answered by AI
Share this study with friends
Copy Link
Messenger